Duopharma shares up in early trade on strong Q1 results
KUALA LUMPUR: Duopharma Biotech Bhd's share price rose on Friday morning following its robust result for the first quarter of financial year 2025 (1Q 2025) due to a surge in insulin supply and improvements in public sector sales.
At 10.27 am, the company's shares gained three sen, or 2.33 per cent, to RM1.32 with a total of 3.21 million shares traded.
Yesterday, Duopharma reported a higher net profit of RM25.64 million for its 1Q ended March 31, 2025, against RM15.28 million in 1Q 2024, while revenue expanded to RM262.74 million from RM192.97 million previously.
In a note, Kenanga Investment Bank Bhd said Duopharma is poised to benefit from a full year of contribution in 2025 from the approved products purchase list (APPL) contracts, further boosting revenue and tilting its sales mix higher toward public sector sales.
"We like the company for its business model, encompassing the entire spectrum of the pharmaceutical value chain and dominant local manufacturer of generic drugs in terms of sales volume and value," it said.
Meanwhile, RHB Investment Bank Bhd believes that Duopharma's prospects will continue to be underpinned by the recent additional contract win from the Ministry of Health (MOH) for the supply of pharmaceutical products under the APPL contract, with a combined estimated contract value of RM684 million.
"A higher budget allocation to MOH, which should boost Duopharma's sales to the public sector, ought to be another positive," it added.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malay Mail
3 days ago
- Malay Mail
Fahmi says MCMC to monitor online vape sales on Facebook, WhatsApp amid rising health concerns
PUTRAJAYA, June 5 — The Communications Ministry, through the Malaysian Communications and Multimedia Commission (MCMC), will monitor online sales of vape and e-cigarette products following increased bans on vape use in several states and concerns over the presence of synthetic substances in these products. Communications Minister Datuk Fahmi Fadzil said the issue was raised during today's Cabinet meeting and is being reviewed by the Health Ministry (MoH). 'At the same time, I will direct MCMC to examine the online sale of such products. We have found that these sales are largely conducted on platforms like Facebook and WhatsApp. 'Any enforcement action will certainly involve the Domestic Trade and Cost of Living Ministry (KPDN),' he told a weekly press conference here today. Fahmi said while vape-related issues fall under the Health Ministry's jurisdiction, the Communications Ministry will monitor the use of social media as a sales platform, particularly for e-cigarette products. 'Insya-Allah, MCMC will prepare a report on this matter, and the Communications Ministry will present it to the Cabinet for further discussion,' he said. He also reaffirmed the Communications Ministry's commitment to working closely with MoH and KPDN to ensure a safer internet environment, particularly for children and families, by addressing issues such as vape and e-cigarette advertisements. — Bernama
The Sun
5 days ago
- The Sun
Duopharma Biotech secures halal certification for biosimilar anaemia treatment
KUALA LUMPUR: Duopharma Biotech Bhd has achieved another milestone in the halal pharmaceutical sector with the halal certification of a biosimilar product used to treat anaemia in patients with chronic renal failure. The certification, awarded by the Department of Islamic Development Malaysia (JAKIM), strengthens Duopharma's position at the forefront of Malaysia's halal pharmaceutical sector. Group Managing Director Leonard Ariff Abdul Shatar said the product is used in adult and paediatric patients undergoing haemodialysis or the predialysis stage. It is currently supplied to both public and private healthcare facilities nationwide. 'This certification marks a key advancement in the company's biologics journey and will further motivate our efforts to provide consumers and patients with access to medicines and therapies that are assured safe and effective, high in quality, hygienic and halal from the start,' Leonard Ariff said referring to the product which is manufactured at Duopharma's plant in Klang. He added that the certification is timely, given the rising number of dialysis patients in Malaysia. The Ministry of Health projects that over 106,000 Malaysians may require dialysis by 2040, with more than 10,000 new cases annually if current trends persist. Duopharma has been a pioneer in the biologics, having launched Malaysia's first Phase 3 clinical trial for an Epoetin Alfa biosimilar in 2014 with South Korea's Pangen Biotech Inc. In 2018, it became the first Malaysian company to install a biologic pre-filled syringe production line. The company also promotes the halal pharmaceutical agenda globally through the annual Halal Pharmaceuticals Symposium, which it has hosted since 2016, bringing together global experts, regulators and industry leaders to advance halal integration in the healthcare system.
The Sun
5 days ago
- The Sun
Duopharma Biotech secures halal cert for anaemia treatment
KUALA LUMPUR: Duopharma Biotech Bhd has achieved another milestone in the halal pharmaceutical sector with the halal certification of a biosimilar product used to treat anaemia in patients with chronic renal failure. The certification, awarded by the Department of Islamic Development Malaysia (JAKIM), strengthens Duopharma's position at the forefront of Malaysia's halal pharmaceutical sector. Group Managing Director Leonard Ariff Abdul Shatar said the product is used in adult and paediatric patients undergoing haemodialysis or the predialysis stage. It is currently supplied to both public and private healthcare facilities nationwide. 'This certification marks a key advancement in the company's biologics journey and will further motivate our efforts to provide consumers and patients with access to medicines and therapies that are assured safe and effective, high in quality, hygienic and halal from the start,' Leonard Ariff said referring to the product which is manufactured at Duopharma's plant in Klang. He added that the certification is timely, given the rising number of dialysis patients in Malaysia. The Ministry of Health projects that over 106,000 Malaysians may require dialysis by 2040, with more than 10,000 new cases annually if current trends persist. Duopharma has been a pioneer in the biologics, having launched Malaysia's first Phase 3 clinical trial for an Epoetin Alfa biosimilar in 2014 with South Korea's Pangen Biotech Inc. In 2018, it became the first Malaysian company to install a biologic pre-filled syringe production line. The company also promotes the halal pharmaceutical agenda globally through the annual Halal Pharmaceuticals Symposium, which it has hosted since 2016, bringing together global experts, regulators and industry leaders to advance halal integration in the healthcare system.
